BridgeMD
New treatment option for Osteoarthritis, Knee
Official title Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients
ClinicalTrials.gov ID: NCT06466850
What this study is testing
What is Exosome?
Exosome is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for osteoarthritis, knee.
Also referred to as EVs.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Present research focuses on the potential of exosomes, which are small vesicles secreted by mesenchymal stem cells (MSCs), as a therapeutic approach for osteoarthritis (OA). OA is a degenerative joint disorder characterized by the destruction of cartilage and loss of extracellular matrix.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 45 to 75
You may be able to join if
- Chronic history (for at least 3 months) of knee joint pain
- Body mass index (BMI) between 21.5 and 29.5
- Radiographically documented knee osteoarthritis of grades 1 to 3 (Kellgren-Lawrence (K-L) radiographic classification scale)
You likely can't join if
- Rheumatoid arthritis and other rheumatic diseases
- Varus or valgus more than 10 degrees; lateral subluxation of the patella
- Deformity at the joint levels or adjacent to the knee due to fracture or any other injury
- Complete rupture of the ligament and meniscus leading to laxity or locking
- Serious systemic, oncohematological, autoimmune diseases; history of severe allergy; serious failure of vital organs, inability to walk
- Hyaluronic acid infiltration within the previous six months
See the full eligibility criteria
- Chronic history (for at least 3 months) of knee joint pain
- Body mass index (BMI) between 21.5 and 29.5
- Radiographically documented knee osteoarthritis of grades 1 to 3 (Kellgren-Lawrence (K-L) radiographic classification scale)
- Rheumatoid arthritis and other rheumatic diseases
- Varus or valgus more than 10 degrees; lateral subluxation of the patella
- Deformity at the joint levels or adjacent to the knee due to fracture or any other injury
- Complete rupture of the ligament and meniscus leading to laxity or locking
- Serious systemic, oncohematological, autoimmune diseases; history of severe allergy; serious failure of vital organs, inability to walk
- Hyaluronic acid infiltration within the previous six months
- Hemoglobin levels \<10 g/dL;
The study team makes the final eligibility decision.
Where it's taking place
- Isfahan, Iran
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 45 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Isfahan, Iran. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.